Sorafenib

While the Sorafenib drug is not a big opportunity for Natco, approval from Kothur plant is a big positive, says Praful Bohra of Religare Capital Markets.

YK Hamied: Cipla's one-man army

YK Hamied has public health on the top of his agenda. In his effort to make drugs affordable, he is not afraid to take on the biggies.

Bayer fights courts for Nexavar as cheaper rivals take over

German drugmaker Bayer may be fighting it out in the courtroom to defend its patent rights on cancer drug Nexavar. But out in the market, it's already lost considerable market share to cheaper variants from Cipla and Natco.

Compulsory license forces MNC pharma to rework India plan

Compulsory license granted to Natco has left the Indian pharma industry with a hard choice to make - cut prices, or quit selling the drug. To counter this drug-makers are changing strategies, reports CNBC-TV18's Archana Shukla.

Natco wins compulsory license from Bayer for cancer drug

In a landmark judgement by India's Patent Office, Natco Pharma has won a compulsory license from Bayer for patent protected anti-cancer drug Nexavar, chemically known as Sorafenib.